Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin PK in Critically Ill Patients on CVVHDF
NCT01171547Phase 2Unknown
- Sponsor
- University of Zurich
- Start
- Feb 2010
- Primary completion
- Feb 2010
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daptomycin in Bacteremia, sponsored by University of Zurich. Primary endpoint: Daptomycin plasma concentrations and pharmacokinetics at Day 5. Status: unknown.
02
Drugs
daptomycin
03
Conditions
Bacteremia
Beyond the preview
Go deeper on NCT01171547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171547.